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TRIGGERSEP Network
Abstract 
Background:  We aimed at assessing the benefit-to-risk ratio of activated protein C (drotrecogin-alfa activated, DAA) 
and corticosteroids, given alone or in combination, in patients with septic shock.
Methods:  We implemented an investigator-led, publicly funded, multicenter, randomized according to a 2 × 2 fac-
torial design, placebo-controlled, double-blind trial in four parallel groups in which adults with persistent septic shock 
and no contraindication to DAA were assigned to either DAA alone (24 mg/kg/h for 96 h), or hydrocortisone (50 mg 
intravenous bolus q6 for 7 days) and fludrocortisone (50 µg once daily through the nasogastric tube for 7 days) alone, 
or their respective combinations, or their respective placebos. Primary endpoint was 90-day mortality rate. Follow-up 
duration was 6 months. Statistical analysis was planned to be performed in intent-to-treat once after all participants 
completed 180-day follow-up and according to the 2 × 2 factorial design.
Results: The first patient was recruited in September 2008. The trial was suspended on October 25, 2011, owing to 
the withdrawal from the market of DAA. At this time, 411 patients had been enrolled. On May 17, 2012, the continua-
tion of the trial on two parallel groups was approved by all legal authorities with the aim of investigating the benefit-
to-risk ratio of corticosteroids. On June 30, 2014, the trial was suspended again by the study sponsor upon request 
of the independent data and safety monitoring board. Recruitment restarted on October 7, 2014, after any safety 
concern was ruled out. Finally, the trial was completed on June 23, 2015, with the recruitment of 1241 patients.
Conclusions: This report details the design, statistical plan and conduct of a randomized controlled trial of hydrocor-
tisone and fludrocortisone in septic shock.
Trial registration The trial was registered at ClinicalTrials.gov under NCT00625209
Keywords: Septic shock, Clinical trial, Design, Ethics, Corticosteroids
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Background
Septic shock is now defined by a vasopressor requirement 
to maintain a mean arterial pressure ≥65  mmHg and 
serum lactate >2 mmol/l in the absence of hypovolemia 
[1] (it was defined by the need for vasopressors to restore 
cardiovascular homeostasis [2] at the time the protocol 
was planned). Its mortality and sequalae remain unac-
ceptably high with roughly one out of two patients dying 
within 1  year and half of survivors suffering from cog-
nitive decline [3]. International guidelines recommend 
immediate source control and antibiotics, fluid resuscita-
tion and norepinephrine [4].
 Drotrecogin-alfa activated (DAA) was the only mar-
keted therapy for sepsis after promising early findings [5]. 
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Subsequent investigations failed to reproduce survival 
benefit from this drug in sepsis [6] or in septic shock [7, 
8].
Corticosteroids have been used for more than 60 years, 
mainly in inflammatory conditions, autoimmune diseases 
or cancer. They have also been used in infectious dis-
eases and sepsis. Corticosteroids have pleiotropic effects 
including immune modulation, metabolic and cardio-
vascular effects. So far, sepsis trials have failed to rule in 
or out survival benefit from corticosteroids. Most phy-
sicians and researchers would agree against using short 
course (<3 days) of high dose (>400 mg per day of hydro-
cortisone or equivalent) in sepsis [4]. Treatment with 
≤400  mg per day of hydrocortisone (or equivalent) for 
≥3 days has variably been associated with survival ben-
efit [9]. The two largest trials of corticosteroids for septic 
shock with 300 [10] and 500 [11] patients, respectively, 
reported treatment benefits in terms of hemodynamics 
and organ functions. One trial showed survival benefit 
in septic shock and blunted cortisol response to cortico-
trophin [10]. There were remarkable differences in trials’ 
design (Table  1). Current guidelines suggest restricting 
hydrocortisone to patients who are poorly responsive to 
vasopressors, not using fludrocortisone and not based on 
Synacthen test [4].
Description of the study design
Clinical question and trial objectives
On the one hand, there was a strong rationale for using 
DAA or corticosteroids in sepsis [12]. DAA may act via 
direct immunomodulation and by counteracting sepsis-
induced hypercoagulopathy [12, 13]. It was associated 
with survival benefit in a phase III trial in severe sepsis 
[5]. The hypothalamic–pituitary–adrenal (HPA) axis was 
identified as the main endogenous counter-regulator of 
inflammation [14]. Then, disrupted HPA axis and exag-
gerated inflammation may favor multiple organ failure 
and death in sepsis [15]. Corticosteroids were associated 
in Ger-Inf-05 [10], a phase III trial of hydrocortisone plus 
fludrocortisone, with survival benefit in septic shock and 
post-corticotrophin increase in cortisol levels ≤9  µg/dl, 
so-called non-responders [16].
On the other hand, there was equipoise among physi-
cians about routine use of DAA and corticosteroids [17, 
18]. Although DAA was approved for sepsis, failure to 
confirm its benefit in mild sepsis [6] yielded controversy 
about its benefits and risks with limited use in routine 
practice. Likewise, CORTICUS cast doubt about the ben-
efit of hydrocortisone [11].
Therefore, the activated protein C and corticoster-
oids for human septic shock (APROCCHSS) trial aimed 
at evaluating in septic shock the benefit-to-risk ratio of 
DAA and corticosteroids, given alone or in combination, 
and any interaction between response to corticosteroids 
and non-responder status.
Study design
We designed an investigator-led, publicly funded, multi-
center, randomized, 2 ×  2 factorial, placebo-controlled, 
double-blind trial in four parallel groups.
Selection of study population
Evidence suggested greater benefit from DAA or corti-
costeroids in septic shock than in sepsis, in adults than in 
children, and when administered within 24 h [12]. In rou-
tine practice, physicians may consider adjunct therapy 
after optimal management of sepsis source and of organs 
function [2].
Therefore, were eligible in the trial, adults admitted to 
the intensive care unit (ICU) for <7 days and with indis-
putable or probable septic shock [2] for <24  h. Septic 
shock was defined by (1) clinically or microbiologically 
documented infection, (2) Sequential Organ Failure 
Assessment (SOFA) [19] score ≥3 for ≥2 organs for ≥6 
consecutive hours, (3) treatment for ≥6 h with catecho-
lamines (≥0.25  µg/kg/min or ≥1  mg/h of norepineph-
rine, epinephrine or any other vasopressor) to maintain 
systolic (SBP) ≥90 mmHg or mean blood pressure (MBP) 
≥65  mmHg. Patient’s informed consent or next of kin 
assent was obtained before inclusion whenever possible. 
Otherwise, deferred consent from patients was recorded 
[20].
Owing to the risk of bleeding with DAA [21], non-
inclusion criteria were (1) surgical procedure ≤7  days; 
(2) gastrointestinal bleeding ≤6  weeks; (3) chronic liver 
disease; (4) trauma ≤3 months; (5) any intracranial mass, 
stroke or head injury ≤3  months; (6) thrombocytope-
nia <30,000/mm3; (7) formal indication for anticoagula-
tion except venous thromboembolism prophylaxis which 
should be continued whenever indicated; (8) any other 
condition with increased risk of bleeding, as per patient’s 
physician. Owing to uncertainty of effects of DAA or 
corticosteroids in pregnant women and in newborns, 
patients were not included in case of pregnancy or lacta-
tion. Additional non-inclusion criteria were (1) patients 
with palliative goals, (2) underlying fatal (≤1  month) 
condition, (3) patients currently taking corticosteroids 
(30  mg prednisone equivalent ≥1  month), (4) known 
hypersensitivity to DAA, (5) no affiliation to social 
security.
A priori defined subgroups of interest to explore 
survival benefits from corticosteroids were: (1) non-
responders, i.e., patients who increase their cortisol levels 
by 9 µg/dl or less at 30 and 60 min following 250 µg intra-
venous bolus of corticotrophin; (2) community-acquired 
pneumonia; (3) acute respiratory distress syndrome 
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(ARDS). Indeed, it was expected that non-responders, 
patients with community-acquired pneumonia or ARDS 
may be more likely to draw survival benefit from corti-
costeroids [9].
Study interventions
DAA was infused intravenously at 24 μg/kg/h from foil-
wrapped bags for 96  h. Infusion was interrupted 2  h 
before any percutaneous procedure or major surgery and 
resumed 1 or 12  h later, respectively, in the absence of 
bleeding complication. Identical blinded volume of 0.9 % 
saline was used as placebo for DAA.
Type, dose and duration (7  days) of corticosteroids 
were determined according to Ger-Inf-05 [10] and not 
to CORTICUS [11]. Hydrocortisone was administered as 
50  mg intravenous bolus every 6  h, and 50  µg tablet of 
fludrocortisone was given via the nasogastric tube once 
daily in the morning. Placebos of French commercial 
forms of hydrocortisone and fludrocortisone were man-
ufactured for the requirements of the trial. Active and 
placebo drugs had similar aspects (checked and certified 
by qualified persons for each batch), i.e., vials of white, 
freeze-dried powder for parenteral use of hydrocortisone 
hemisuccinate 100  mg or placebo, and tablets for oral 
fludrocortisone 50 µg or placebo in blisters of ten.
Co-interventions were harmonized across centers 
according to 2008 Surviving Sepsis Campaign guide-
lines [22]. Blood glucose levels were monitored at least 
every 4 h and maintained at ≤150 mg/dl by intravenous 
infusion of insulin. Intravenous broad-spectrum antibi-
otics were given after drawing specimen from all poten-
tial sites of infection and adjusted to actual pathogens 
whenever needed. Investigators followed guidelines for 
the prevention of superinfection [23]. Open-labeled cor-
ticosteroids and non-steroidal anti-inflammatory drugs, 
open-labeled DAA, anti-thrombin III and any antico-
agulant (except venous thromboembolism prophylaxis) 
were discouraged. The use of antiplatelet agents was 
left at physicians’ discretion. Neuromuscular blockade 
agents were discouraged, except in the first 24 h of refrac-
tory hypoxia. The investigators were provided with pub-
lished guidelines for the management of septic shock. 
We systematically recorded, on a daily basis during the 
first week post-randomization, in the case report form, 
blood glucose levels and dose and duration of insulin, 
source and pathogens identification and dose and dura-
tion of any antibiotic administered to the patients, type 
and dose of fluid therapy and of vasopressor therapy, 
score of sedation and delirium and use of any sedation 
or neuromuscular blocking drug, dose and duration of 
any anticoagulant, and type, dose and reason for use of 
any open-labeled corticosteroids. These data will allow 
careful examination of the adherence of investigators 
to guidelines for co-interventions. In addition, at each 
investigators meeting, these guidelines were systemati-
cally discussed to reinforce compliance.
Randomization and blinding
Randomization was centralized, through a secured Web 
site, and stratified according to center, using permutation 
blocks where size was unknown by investigators. Patients 
were randomly allocated to receive DAA and hydrocor-
tisone plus fludrocortisone, placebo of DAA and hydro-
cortisone plus fludrocortisone, or DAA and placebos of 
hydrocortisone and fludrocortisone, or all placebos. The 
day of randomization was considered as study day 0. The 
system printed prefilled prescriptions and, during the 
first part of the trial, individual infusion tables of DAA/
placebo for care unit and pharmacy.
Treatment boxes were coded and masked centrally. 
Corticosteroids or placebos were sealed in sequentially 
numbered, identical boxes containing 30 vials of lyophi-
lized hydrocortisone and 30 ampoules of injectable water, 
and a blister package with 10 tablets of fludrocortisone or 
its placebo. Each box has a detachable sticker for tracea-
bility of dispensing by hospital pharmacy and for admin-
istration by nurses.
Numbered boxes of DAA/placebo were also prepared 
on site. One patient received one corticosteroid/placebo 
box and one DAA/placebo box with the same randomiza-
tion number. All study drugs were shipped to participat-
ing sites by AGEPS, AP-HP, Paris, France. The sequence 
was concealed from patients, staff members, investi-
gators, members of independent data safety monitor-
ing board (DSMB), sponsor and local pharmacists for 
corticosteroids.
Definitions
Organ system failure was defined for each of the 6 major 
organ systems as a SOFA score of 3 or 4 points (on a 
scale of 0–4 for each organ system, for an aggregate 
score of 0–24, with higher scores indicating more severe 
organ dysfunction) [19]. Reversal of shock was defined as 
MBP ≥ 60 mmHg for ≥24 h after cessation of vasopres-
sor. Superinfection was defined using standard criteria 
[23], as a new infection occurring ≥48 h after randomi-
zation. New sepsis was defined as a new episode with 
microbiologic confirmation. New septic shock was defined 
as a new episode of septic shock after reversal of the ini-
tial episode.
Investigated parameters and follow-up
Baseline data
We systematically recorded (1) demographic and anthro-
pometric data; (2) time of hospital and ICU admis-
sions; (3) location prior to ICU admission (community, 
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hospital, long-term care facility); (4) co-morbidities 
using Acute Physiology and Chronic Health Evaluation 
(APACHE) disability scale [24] and McCabe class [25]; 
(5) severity of illness using vital signs, Simplified Acute 
Physiology Score (SAPS) II [26] and SAPS III [27] and 
SOFA score [19]; (6) core temperature; (7) type and dose 
of any antibiotics in the week before randomization; (8) 
type and dose of vasopressors and inotropic drugs; (9) 
time from shock onset; (10) hematologic, chemical data, 
blood gas analyses and arterial lactate levels; (11) Gram 
examination and cultures of samples from any suspected 
site of infection; (12) plasma cortisol levels before, 30 and 
60 min after 250 µg intravenous bolus of corticotrophin.
Follow‑up
Patients were followed up for 180  days. We recorded 
daily from randomization to study day 7, at day 10, day 
14, day 21 and day 28 or at ICU discharge (depending on 
which occurred first): (1) vital signs; (2) muscular dis-
ability rating score (MDRS) ranging from 1 to 5 with 1 
meaning no deficit, 2 minimal deficit or atrophy, 3 mild-
to-moderate distal deficit, 4 mild-to-moderate proximal 
deficit and 5 severe proximal deficit or atrophy [28]; (3) 
CAM-ICU scale [29]; (4) any bleeding; (5) results from 
standard laboratory tests; (6) cultures of specimens from 
any new suspected site of infection; (7) cumulated doses 
of intravenous insulin (UI/L/24 h), minimal and maximal 
infusion rates (µg/h; given for at least 1 h) of catechola-
mine, blood product transfusion, mode of ventilation 
(spontaneous breathing, noninvasive or invasive mechan-
ical ventilation), need for and mode of renal replacement 
therapy and treatment with statins; (8) SOFA scores. 
If the patient was sedated, MDRS score and CAM-ICU 
were assessed ≥6 h after interruption of sedation. In case 
of abnormal neurological status, brain imaging (CT scan 
or magnetic resonance imaging) was performed.
Mid-term sequalae were assessed at day 90 and day 180 
post-randomization, by means of the Short-Form Gen-
eral Health Survey [30], the Impact of Events scale [31] 
and Hospital Anxiety and Depression scale [32].
Biobanking
Fifteen milliliters of blood was sampled at baseline, day 1, 
day 4 and day 7. Then, aliquots of serum and plasma were 
stored at −80 °C, and DNA was stored at +4 °C at each 
participating hospital. On a regularly basis, samples were 
shipped to a core laboratory.
Study endpoints
Ninety-day mortality was the primary endpoint. 
Although most of sepsis-related deaths occur within 
28  days, increasing evidence suggests that sepsis 
continues to kill patients beyond day 28. In previous sep-
sis trials, significant number of 28-day survivors died 
during the same hospital stay [33].
 Secondary endpoints included (1) death rates at ICU 
and hospital discharge, at day 28 and day 180; (2) propor-
tion of patients with decision to withhold/withdraw care; 
(3) time to wean off vasopressors, i.e., shock reversal; (4) 
number of days alive (up to 28 and 90 days) and free of 
vasopressors; (5) time to SOFA score <6; (6) number of 
days alive (up to 28 and 90 days) and with SOFA score <6; 
(7) time to wean off mechanical ventilation; (8) number 
of days alive (up to 28 and 90 days) and free of mechani-
cal ventilation; (9) length of ICU and hospital stay in all 
patients and in survivors.
Safety outcomes included occurrence up to 90 days of 
superinfection, new sepsis, new septic shock, gastroin-
testinal bleeding and neurological sequalae (cognitive 
impairment and muscles weakness) at ICU and hospital 
discharge, at day 90 and at day 180.
Sample size calculation and statistical analysis plan
We anticipated a 90-day mortality rate among patients 
with septic shock of 45  % [10]. Using 2  ×  2 facto-
rial design with a bilateral formulation, 320 patients 
per group (i.e., total of 1280 patients) were needed to 
detect an absolute reduction of 10  % of 90-day mortal-
ity (α  =  0.05 and power at 95  %) with either DAA or 
corticosteroids.
After DAA withdrawal from the market, we analyzed 
the effects of DAA in patients included before trial sus-
pension without analyzing the effects of corticosteroids 
[8].
As initially planned in the protocol, statistical analyses 
will be performed in intent-to-treat after all participants 
have completed 180-day follow-up and according to the 
2 ×  2 factorial design. This analysis will allow assessing 
the interaction between DAA and corticosteroids and 
corticosteroids effect (on the basis of a comparison of 2 
groups of approximately 620 patients) with the initially 
planned power. The effect of DAA will be reanalyzed on 
the basis of a comparison including 208 patients with 
DAA and 1033 patients without DAA with a statistical 
power of 76 %.
For continuous variables, means and SD or median 
(IQR), in case of non-normality of distribution, will be 
reported. For categorical variables, number of patients 
in each category and corresponding percentages will be 
given. Missing data will not be replaced.
The effects of treatments on frequency of fatal events 
(mortality rates at day 28, at day 90, at discharge from 
ICU or from hospital and at day 180) will be compared 
using a logistic regression. The same analysis will be used 
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for the proportion of patients with decision to withhold/
withdraw care and safety outcomes. An analysis of vari-
ance will be used to compare continuous variables as 
length of stay. Cumulative event curves (censored end-
points) will be estimated with Kaplan–Meier procedure, 
and Cox model will be used to compare treatments 
effects (time to death, time to wean off vasopressors and 
mechanical ventilation, time to a SOFA score <6). Analy-
sis of variance will be used to compare number of days 
alive and free of vasopressors, mechanical ventilation, 
and with a SOFA score <6.
The same analyses will be conducted for subgroups 
unless the numbers of patients are insufficient. In this 
case, statistical methods will be adapted according to 
sample sizes.
The statistical analysis plan will be revised after blind 
review of data and before access to randomization list. 
All analyses will be conducted with SAS statistical soft-
ware (version 9.4; Cary, NC, USA).
Study Organization and Funding
The protocol was approved by all investigators on June 
2007. It was independently approved for scientific and 
financial aspects by the national jury of the Clinical 
Research Hospital Program on October 2007, and the 
Ministry of Health confirmed funding under contract 
number P 070128. The protocol and qualification of all 
investigators were approved by the Ethics Committee 
(Comité de Protection des Personnes, CPP) of Saint-Ger-
main-en-Laye, France, on November 22, 2007. The CPP 
allowed for waiver of consent and deferred consent.
DSMB was set up prior to recruitment of the first 
patient, included experts in critical care medicine, infec-
tious diseases, pharmacology and statistics, had full 
access to raw data and met on a regular basis.
Data monitoring was performed by the sponsor (AP-
HP; Délégation à la Recherche Clinique d’Ile de France, 
DRRC). AP-HP had full access to patients’ charts and 
checked all data recorded onto the electronic case 
report form (CRF) against original chart. The trial used 
a Web-based electronic CRF (Telemedecine Technology, 
France).
Data management and statistical analysis were per-
formed independently of the sponsor and of investiga-
tors by specialized Biometry unit (Unité de Biométrie, 
INSERM 1414 Clinical Investigation Centre, Rennes Uni-
versity Hospital, Rennes 1 University, Rennes France).
Institutional pharmacists (AGEPS) were responsible 
for obtaining corticosteroids and their placebos, shipping 
study drugs to participating sites and getting back unused 
drugs. They were responsible for accurateness of blinding 
and pharmaceutical organization of the trial.
Vials of lyophilizate for parenteral use of hydrocor-
tisone hemisuccinate 100  mg or placebo and diluent 
ampoules were obtained from Serb pharmaceutical 
company. Active and placebo tablets for oral route of 
fludrocortisone 50  µg were supplied from French com-
mercial market under responsibility of AGEPS. Due to 
the study length, fludrocortisone shelf-life and commer-
cial changes, different companies were involved: EP-HP 
AP-HP, Genopharm and HAC pharma company. No 
change in formulation, specifications or quality con-
trols occurred. This was approved by National Agency 
for Drug Safety (ANSM, Saint-Denis, France). Anticipa-
tion of manufacturing campaigns avoided any supply 
disruption.
Several documents were provided to caregivers and 
pharmacists to ensure safety, compliance and good use 
of study drugs: prefilled prescriptions (with patient 
ID, weight, treatment number, DAA/placebo infusions 
description when required), DAA/placebo personal-
ized administration table (number of perfusions, dose/
perfusion, durations, etc.), DAA/placebo preparation 
sheet for hospital pharmacists, nurse tracking adminis-
tration file, pharmacy dispensing and return book. All 
documents were revised after DAA withdrawal from the 
market.
A total of 65 ICU were authorized to recruit patients, 
19 at university hospitals and 46 at community hospi-
tals. Among them 34 participated actively in recruiting 
patients in this trial.
Trial registration
The trial was registered on February 19, 2008, before 
inclusion of the first patient, at ClinicalTrials.gov under 
the number NCT00625209.
Study conduct
Study suspension and completion
The first patient was recruited on September 2, 2008, 
and the last patient on June 23, 2015. The study was 
suspended twice. Study sponsor, Steering committee, 
investigators, pharmacists and study statisticians always 
remained blinded to study treatments.
On October 25, 2011, while the trial was still recruit-
ing, Lilly announced DAA withdrawal from the mar-
ket [34]. Since DAA was no longer available and Lilly 
refused to provide the drug for our study, AP-HP 
immediately suspended the study. The Steering com-
mittee, while remaining blinded to study treatments, 
proposed to analyze effects of DAA in the 411 patients 
included before trial suspension without analyzing 
effects of corticosteroids as there was no interaction 
between the two treatments. There was no benefit from 
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DAA [8]. The Steering committee recommended trial’s 
continuation to assess effects of corticosteroids. These 
recommendations were approved by ethics committee 
on February 10, 2012, and by ANSM on April 18, 2012. 
Inclusions into the study restarted on May 18, 2012. 
On June 24, 2013, additional funding was granted from 
Ministry of Health (contract P 12-002-0030; AOM 
07008).
On July 22, 2014, AP-HP decided to suspend the trial 
after DSMB requested careful examination of serious 
adverse events and checking study drugs quality. Subse-
quently, detailed description of all serious adverse events 
was provided for all patients. Meanwhile, independ-
ent investigations confirmed study drugs quality. DSMB 
advised on October 1, 2014, AP-HP to restart the trial. 
The trial continuation was approved on October 7, 2014 
by ANSM and on November 13, 2014 by CPP. The trial 
was completed by December 23, 2015, after the last 
patient reached 180 day post-randomization. Figure  1 
shows the actual recruitment curve.
In April 2014, ANSM announced a shortage of Syn-
acthen 0.25 in Europe. The trial was not suspended. 
Investigators and sites’ pharmacists asked to continue 
sampling for random cortisol measurement whenever 
Synacthen was not available at their hospital.
Study protocol amendments
There were 29 amendments to study protocol (Table 2). 
They were approved by investigators, study statistician, 
AP-HP, CPP and ANSM.
The main substantial modification to the protocol was 
approved in October 2011, following DAA withdrawal 
from the market. Two study arms, i.e., active DAA and 
its placebo, were stopped, and the design was modified 
to a two parallel groups. As sample size was originally 
computed to show a 10  % absolute reduction in 90-day 
mortality between corticosteroids versus placebo-treated 
patients, or DAA versus placebo-treated patients, there 
was no need to modify it. DAA-related exclusion crite-
ria were no longer justified and withdrawn (Table  2). 
This last amendment to the protocol was associated with 
a significant (p < 0.001) rise in recruitment rate into the 
study. There were 0.42 ± 0.89 (range 0–9, median 0 [0;1]) 
and 0.89  ±  1.46 (range 0–11, median 0 [0;1]) patients 
per site per month, before and after study amendment, 
respectively.
Study monitoring
The Steering committee had monthly conference calls. 
The study site coordinator (Raymond Poincaré hospital) 
provided on-demand 24/7 services via phone calls or 
Fig. 1 Cumulative number of enrolled patients in the trial
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emails to advise investigators about patients’ eligibility 
or any other issues that may have risen between rand-
omization and 180-day follow-up. There were a total of 
28 face-to-face investigators meeting in which trial pro-
tocol and procedures were systematically recalled and 
investigators adherence and compliance to them dis-
cussed. A monthly electronic newsletter informed inves-
tigators on trial conduct and on any new information 
from sepsis literature.
DSMB met 5 times. DRRC organized data monitor-
ing and quality audits. Baseline characteristics, eligibil-
ity criteria, primary outcome and serious adverse events 
reported in the CRF were systematically checked against 
original chart for all research participants. In addition, 
for one-third of study population, all data reported in 
CRF were validated against patient’s original chart. Seri-
ous adverse events and major protocol violations were 
reported to DRRC, ANSM and CPP.
The study coordinator had quarterly face-to-face meet-
ing with DRRC, AP-HP, independent pharmacists to 
monitor trial conduct according to highest standard for 
protection of research participants.
All randomized patients completed follow-up for the 
primary outcome and 180-day mortality data.
Discussion
This trial was designed to assess the role of DAA and cor-
ticosteroids in adult septic shock. Evaluation of DAA was 
terminated early owing to its withdrawal from the mar-
ket by Lilly [34]. We found no evidence for any benefit 
from DAA [8]. Owing to the lack of interaction between 
DAA and corticosteroids, the trial continued to allow 
evaluation of corticosteroids. The study was suspended 
on request of DSMB to check safety issues. The two trial 
suspensions had no impact on its conduct, except delay-
ing its completion. There were several amendments to 
the protocol mainly related to DAA. In particular, after 
DAA withdrawal from the market, corresponding exclu-
sion criteria were removed and trial design changed for a 
two-parallel groups’ design. This amendment accelerated 
the recruitment rate into the trial. Then, we will explore 
any interaction between this change in the protocol and 
response to corticosteroids.
This trial replicated as much as possible Ger-Inf-05 [10] 
contrasting with CORTICUS [11] and ADRENAL [35] 
trials (Tables  1, 2). APROCCHSS trial has investigated 
the effects of hydrocortisone and fludrocortisone at the 
same doses, durations and routes of administration than 
for Ger-Inf-05 [10]. Likewise, it focused on patients with 
persistent vasopressor dependency and organ failure. 
Finally, non-responders [16] were an a priori defined sub-
group in analyzing corticosteroids effects.
Risk of bias assessment
First, selection biases were minimized. Allocating inter-
ventions to research participants used a random list 
which sequence was computer-generated by an independ-
ent statistician. To prevent forth knowledge of forth allo-
cation, randomization was centralized through a secured 
Web site and used permutation blocks where size was 
not known by patients, nurses and physicians, investiga-
tors, pharmacists, and study sponsor. Thus, the allocation 
sequence was adequately concealed. Second, to minimize 
performance biases, we used a centralized procedure for 
masking corticosteroids and their placebos. Sites pharma-
cists received sealed boxes containing either active drugs 
or placebos in identical forms. Blood glucose levels were 
kept of ≤150 mg/dl. Previous experiences from this group 
of investigators [10, 36] as from others [11] demonstrated 
that nurses, physicians and investigators can remain 
appropriately blinded to corticosteroids administration. 
Third, to prevent detection biases, for short-term and 
long-term outcomes, hospital staff, investigators, phar-
macists and outcome assessors will remain blinded until 
public release of trial findings. Finally, there were no obvi-
ous attrition biases. There was no lost-to-follow-up for 
mortality data up to 180 days. According to French regu-
lation, vital status of any citizen is publicly available at city 
hall of the town the citizen was born.
Other potential sources of bias may include the fact 
that the study design and statistical analysis plan were 
reported after all patients have been enrolled. This was 
done deliberately to also report the way the trial was 
conducted, in particular any amendment to the pro-
tocol. We did not plan any interim analysis and did not 
perform any. In fact, after the withdrawal of DAA from 
the market, we reported the analysis of the effects of 
this drug after checking for the absence of interaction 
with low-dose steroids. The code was never broken for 
corticosteroids, and all the parties involved in the trial 
remained fully blinded. Therefore, it is unlikely that the 
lack of reporting of the trial protocol before completion 
of recruitment may be a source of bias.
In conclusion, APROCCHSS trial is the only trial 
replicating Ger-Inf-05. Its design and conduct allowed 
appropriate minimization of risk of bias. It will provide 
sufficient reliable data to inform routine practice for 
management of adult septic shock. At the present time, 
the analysis is still pending, and all parties involved in 
this trial remain blinded.
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Table 2 List of amendments to the protocol
Amendments 
number
Changes in protocol CPP  
approval date
ANSM  
approval date
Official version of trial protocol
1 Changes in following exclusion criteria:
 “surgical procedure in the past 7 days” was changed for 
“surgical procedure within 72 h, or any surgery associ-
ated with high risk of bleeding, or a planned surgery 
within 24 h”
 “chronic liver disease” was clarified as “chronic liver 
disease with Child score C”
 “severe thrombopenia” was clarified” as severe throm-
bopenia (<30,000/mm3, before transfusion)
Minor wording modifications in title, study acronym, 
randomization paragraph
Recruitment of 4 additional centers
14/02/2008 27/03/2008 Protocol V2 dated 28/01/2008
2 Recruitment of 1 additional center
Withdrawal of 1 center
12/06/2008 Not applicable Protocol V2 dated 28/01/2008 
unchanged
3 Recruitment of 9 additional centers 03/07/2008 Not applicable Protocol V2 dated 28/01/2008 
unchanged
4 Recruitment of 1 additional center 13/11/2008 Not applicable Protocol V2 dated 28/01/2008 
unchanged
5 The time window for the use of a prepared (i.e., ready 
for infusion) infusion bag of Xigris and of its placebo 
was increased from 14 h to 24 h
12/02/2009 26/12/2008 Protocol V3 dated 11/12/2008
6 Recruitment of 1 additional center
Change in contact details of 3 centers
15/01/2009 Not applicable Protocol V3 dated 11/12/2008 
unchanged
7 Recruitment of 1 additional center 9/04/2009 Not applicable Protocol V3 dated 11/12/2008 
unchanged
8 Recruitment of 2 additional centers 18/06/2009 Not applicable Protocol V3 dated 11/12/2008 
unchanged
9 The exclusion criteria: surgical procedure within 72 h, or 
any surgery associated with high risk of bleeding, or a 
planned surgery within 24 h “was changed for” surgi-
cal procedure within 12 h, or any surgery associated 
with high risk of bleeding
17/09/2009 25/08/2009 Protocol V3.0 dated 20/07/2009
10 Recruitment of 1 additional center 12/11/2009 Not applicable Protocol V3.0 dated 20/07/2009 
unchanged
11 Recruitment of 1 additional center 10/12/2009 Not applicable Protocol V3.0 dated 20/07/2009 
unchanged
12 Recruitment of 1 additional center 11/03/2010 Not applicable Protocol V3.0 dated 20/07/2009 
unchanged
13 Inclusion criteria: admitted to the ICU for <7 days was 
removed.
New exclusion criteria: patients who had a previous 
episode of sepsis during the same hospital stay
Prolongation of the recruitment period
Recruitment of 3 additional centers
Withdrawal of 11 inactive centers
10/06/2010 11/06/2010 Protocol V4 dated 10/05/2010
14 Withdrawal of 4 inactive centers 09/09/2010 Not applicable Protocol V4 dated 10/05/2010 
unchanged
15 Recruitment of 1 additional center 23/11/2010 Not applicable Protocol V4 dated 10/05/2010 
unchanged
16 Recruitment of 1 additional center
Implementation of biobanking: serum, plasma, DNA
Change in informed consent sheet
23/11/2010 09/11/2010 Protocol V6 dated 03/11/2010
Informed consent sheet V1.1 dated 
26/10/2010
17 Recruitment of 1 additional center 13/10/2010 Not applicable Protocol V6 dated 03/11/2010 
unchanged
18 Recruitment of 7 additional centers 13/01/2011 Not applicable Protocol V6 dated 03/11/2010 
unchanged
19 Recruitment of 1 additional center 7/04/2011 Not applicable Protocol V6 dated 03/11/2010 
unchanged
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sant, Alain Cariou, Christian Brun Buisson, Claude Mar-
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Table 2 continued
Amendments 
number
Changes in protocol CPP  
approval date
ANSM  
approval date
Official version of trial protocol
20 Recruitment of 1 additional center 12/05/2011 Not applicable Protocol V6 dated 03/11/2010 
unchanged
20 BIS Following the withdrawal of DAA from the market:
 Study design was modified from a 2 × 2 factorial to a 
two-parallel groups’ trial
 Withdrawal of following exclusion criteria:
  (1) any surgery in the past 12 h, or any surgery associ-
ated with high risk of bleeding;
  (2) chronic liver disease with a Child score C;
  (3) recent trauma;
  (4) any intracranial mass, or stroke or head injury in the 
past 3 months;
  (5) severe thrombocytopenia (<30,000/mm3, before 
platelet transfusion);
  (6) formal indication for anticoagulation, or any other 
condition associated with increased risk of bleeding, 
as appreciated by the patient’s physician
Change in informed consent form
10/02/2012 18/04/2012 Protocol V7 du 30/11/2011
Informed consent sheet V3.0 dated 
05/01/2012
21 Prolongation of recruitment period 05/07/2012 Not applicable Protocol V8 dated 27/06/2012
Informed consent form V3.1 dated 
21/09/2012
22 Recruitment of 2 additional centers 13/09/2012 Not applicable Protocol V9 dated 27/08/2012
23 Recruitment of 2 additional centers Withdrawal of 4 
centers
13/12/2012 Not applicable Protocol V10 dated 04/12/2012
24 Recruitment of 2 additional centers
Removal of exclusion criteria related to XIGRIS
Withdrawal of 5 centers
21/03/2013 22/03/2013 Protocol V11.0 dated 20/02/2013
Protocol V11.1 dated 18/03/2013
25 Minor edits to the informed consent form upon CPP 
request
24/04/2014 Not applicable Protocol V12 du 15/10/2013
Informed consent form V3.2 dated 
21 01 2014
26 Suspension of inclusions upon DSMB request
Changes in DSMB members
18/09/2014 29/08/2014 Protocol V13 dated 24/07/2014
27 Request to restart inclusion following:
(1) demonstration of the quality of study active drugs 
and placebos
(2) advice from DSMB
13/11/2014 07/10/2014 Protocol V13 dated 24/07/2014, 
unchanged
28 Prolongation of trial duration 11/06/2015 Not applicable Protocol V14.0 dated 12/05/2015
CPP comité de protection des personnes, ANSM Agence nationale de sécurité des médicaments et produits de santé
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Quality Assurance: Délégation à la Recherche Clinique, 
Hôpital Saint-Louis, Paris.
Data safety and Monitoring Board: Gérard Nitenberg 
(chair) Jacques Bénichou, Didier Dreyfuss.
Pharmacists: Blandine Lehmann: Département Essais 
Cliniques, AGEPS, AP-HP, Paris.
 
Study centers and investigators
Surname and name of sites 
principal investigator
Study sites details
Annane, Djillali
Fadel, Fouad
Polito, Andrea
Clair, Bernard
Maxime, Virginie
Luis, David
Service de Réanimation médicale
HOPITAL RAYMOND POINCARE
104 BD RAYMOND POINCARE
92380 GARCHES
Quenot, Jean-Pierre Service de réanimation
14 RUE GAFFAREL BP 77908 21079 DIJON 
CEDEX
HÔPITAL F. MITTERRAND
CHU DE DIJON
Megarbane, Bruno Service de Réanimation Médicale et 
Toxicologique
Hôpital LARIBOISIERE
2 rue AMBROISE PARE
75010 PARIS
Siami, Shidasp
Percheron, Stéphanie
Service d’ Anesthésie-réanimation du Dr. 
Lorenzo
CENTRE HOSPITALIER D’ETAMPES
26 AV CHARLES DE GAULLE
91150 ETAMPES
Mignon, Alexandre
Baudin, Francois
Antona, Marion
Meghenem, Alia
Demesmay, Marine
Service d’ Anesthésie Réanimation
Hôpital COCHIN
27 R FAUBOURG ST-JACQUES
75014 PARIS
Forceville, Xavier
Kuba-Kusuti, Jean-Kamiena
Touati, Samia
Service de Réanimation Polyvalente
CENTRE HOSPITALIER DE MEAUX
6 R SAINT FIACRE
77100 MEAUX
Reignier, Jean
Colin, Gwenhaël
Martin-Lefevre, Laurent
Bachoumas, Konstantinos
Henry-Lagarrigue, Matthieu
Yehia, Aihem
Lascarrou, Jean-baptiste
Lebert, Christine
Lacherade, Jean-claude
Service de réanimation
CENTRE HOSPITALIER DEPARTEMENTAL
SITE DE LA ROCHE-SUR-YONLES OUDAIR-
IES
85925 LA ROCHE SUR YON CEDEX 9
Asehnoune, Karim
Loutrel, Olivier
Dumont, Romain
Roquilly, Antoine
Mahe, Pierre-Joachim
Demeure Dit Latte, Dominique
Champin, Philippe
Arnould, Jean François
Cinotti, Raphaël
Le Floch, Ronan
Service d’Anesthésie Réanimation 
chirurgicale,
CHU DE NANTES
19 RUE GENERAL MARGUERITTE, 44000 
NANTES
Surname and name of sites 
principal investigator
Study sites details
Mercier, Emmanuelle
Garot, Denis
Dequin, Pierre François
Perrotin, Dominique
Legras, Annick
Mankikian, Julie
Talec, Patrice
Ehrmann, Stephan
Joret, Aurélie
Lhommet, Claire
Joret, Aurélie
Lhommet, Claire
Rouve, Emmanuelle
Bodet-Contentin, Laetitia
Jouan, Youenn
Salmon-Gandonniere, Charlotte
Service de réanimation polyvalente,
CHU BRETONNEAU,
2, BOULEVARD TONNELLE,
37044 TOURS
Antonini, François
Martin, Claude Denis
Ragonnet, Benoît
Service d’ Anesthésie Réanimation
HOPITAL NORD
Chemin des BOURRELY
13015 MARSEILLE
Brun Buisson, Christian
Razazi, Keyvan
De Prost, Nicolas
Carteaux, Guillaume
Service de Réanimation Médicale
Hôpital HENRI MONDOR
51 AV DE LATTRE DE TASSIGNY
94010 CRETEIL
Wolff, Michel
Mourvillier, Bruno
Timsit, Jean françois
Service de Réanimation - Maladies 
Infectieuses
Hôpital BICHAT CLAUDE BERNARD
46 Rue HENRI HUCHARD
75018 PARIS
Chagnon, Jean-Luc
Ali Ben Ali, Mohamed
Service de Réanimation Polyvalente
C.H. DE VALENCIENNES
114 AV DESANDROUINS
BP 479
59322 VALENCIENNES
Chimot, Loic
Delour, Pierre
Dessalles, Pierre Henri
Monseau, Yannick
Saint-Leger, Mélanie
Bedon-Carte, Sandrine
Service de Réanimation
CENTRE HOSPITALIER PERIGUEUX
80, AVENUE GEORGES POMPIDOU
CS 61205
24019 PERIGUEUX CEDEX
Boulain, Thierry
Mathonnet, Armelle
Bretagnol, Anne
Runge, Isabelle
Barbier, François
Muller, Gregoire
Service de réanimation polyvalente
CHR D’ORLEANS
1, RUE PORTE-MADELEINE –
45000ORLEANS
Francois, Bruno
Clavel, Marc
Vignon, Philippe
Pichon, Nicolas
Fedou, Anne-Laure
Chapellas, Catherine
Galy, Antoine
Service de réanimation polyvalente
CHU LIMOGES
2, AVENUE MARTIN LUTHER KING 87042 
LIMOGES
Timsit, Jean-Francois Service de Réanimation médicale
CHU DE GRENOBLE
Avenue du Maquis du Gresivaudan, 
Pavillon Dauphiné
BP 217
38043 GRENOBLE
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Surname and name of sites 
principal investigator
Study sites details
Misset, Benoit
Garrouste Orgeas, Maité
Philippart, François
Service de Réanimation médicale 
polyvalente
HOPITAL SAINT-JOSEPH
185 R RAYMOND LOSSERAND
75674 PARIS
Souweine, Bertrand
Ait-Hssain, Ali
Service de Réanimation
CHU CLERMONT-FERRAND
58 RUE MONTALEMBERT
BP69
63003 CLERMONT FERRAND
Charpentier, Claire Service de Réanimation chirurgicale
HOPITAL CENTRAL
29 AVENUE DU MARECHAL DE
LATTRE DE TASSIGNY
54037 NANCY
Mignon, Alexandre
Baudin, Francois
Antona, Marion
Meghenem, Alia
Demesmay, Marine
Service d’ Anesthésie Réanimation
Hôpital COCHIN
27 R FAUBOURG ST-JACQUES
75014 PARIS
Petitpas, Franck
Mimoz, Olivier
Nanadoumgar, Hodanou
Service de Réanimation Chirurgicale
HÔPITAL DE LA MILETRIE
2 RUE DE LA MILETRIE
B. P. 577
86021 POITIERS
Chastre, Jean
Combes, Alain
Nieszkowska, Ania
Service de Réanimation Médicale
C.H.U. PITIE SALPETRIERE
47 BOULEVARD DE L’HOPITAL
75013 PARIS
Amathieu, Roland
Levesque, Eric
Réanimations et surveillance continue 
chirurgicales HOPITAL HENRI MONDOR
51 AV DE LATTRE DE TASSIGNY
94010 CRETEIL
Cook, Fabrice Réanimations et surveillance continue 
chirurgicales
HOPITAL HENRI MONDOR
51 AV DE LATTRE DE TASSIGNY
94010 CRETEIL
Constantin, Jean-Michel
Chartier, Christian
Jabaudon, Mathieu
Perbet, Sébatien
Service d’ Anesthésie et réanimation
HÔPITAL HOTEL DIEU
Boulevard Léon Malfreyt
63058 CLERMONT FERRAND CEDEX 1
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